美国一组患有HCC的患者的财务负担
Ruchi Desai1, Yue Jiang2, Lisa B VanWagner3
1Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
肝细胞癌 (HCC) 患者面临着巨大的财务负担,近一半的患者经历了高的总医疗费用. 诸如老年,并发症和特定治疗等因素导致了这种财务压力.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
背景情况:
- 许多癌症的高财务负担被记录在案,但肝细胞癌 (HCC) 患者的数据有限.
- 了解对HCC患者的财务影响对于开发支持性干预至关重要.
研究的目的:
- 描述被诊断为HCC的患者所经历的财务负担.
- 确定与这种患者群体中高财务负担相关的因素.
主要方法:
- 使用IQVIA PharMetrics Plus数据库用于商业保险的HCC患者 (2006-2021年).
- 定义患者的财务责任为允许和支付的保险索赔金额之间的差额.
- 采用多变量后勤回归来确定高总负债 (≥3000美元/年) 和与HCC相关的 (≥1000美元/年) 财务负债的相关性.
主要成果:
- 在HCC诊断后的一年,中位数的财务负债总额为2955美元,其中45%的负债高.
- 最大的财务负担发生在诊断后3个月内.
- 高龄,并发症,肝硬化并发症,全身疗法和肝移植与更高的患者责任感有关.
结论:
- 患有HCC的患者会面临巨大的财务负担.
- 显然需要提高HCC患者的价格透明度和财务咨询服务.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
相关概念视频
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hepatitis
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology
